Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
Date:5/17/2010

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

Cambridge, Mass. (PRWEB) May 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling the phosphatidylinositol 3-kinase (PI3K) pathway and preventing tumor proliferation.

“Our team is quite excited to test this combination in clinical trials given the preclinical data we have produced showing that MM-111 and Herceptin® have very complementary mechanisms of action,” said Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack. “We believe that by combining the two candidates, we have the potential to treat a number of HER2 positive breast cancer patients who are not benefiting from current treatments.”

The Phase 1 /2 study will initially evaluate the human safety and pharmacokinetics of MM-111 in combination with Herceptin® and establish a safe regimen. The Phase 2 portion of the study will then investigate the regimen’s efficacy in the advanced Her2 positive breast cancer patient population. The trial is based on preclinical work showing that MM-111 and Herceptin® positively combine to inhibit the growth of ErbB2 over-expressing breast cancer cells. The Gabrail Cancer Center in Canton, Ohio, Huntsman Cancer Institute in Salt Lake City, Utah, and the Massachusetts General Hospital in Boston, Massachusetts, will part
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
2. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
3. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
4. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 Three ... Energy's 2014 Hydrogen Production R&D Award ... by splitting water using sunlight. , Shared with ... and the University of Nevada, Las Vegas (UNLV), ... developing models of photoelectrochemical solar-hydrogen production and corrosion ...
(Date:8/28/2014)... August 28, 2014 SPIE Fellow Glenn ... and Optical Science and Director of the Center for ... Carolina at Charlotte, and co-founder and Chairman of the ... as the 2015 Vice President of SPIE, the international ... Philip Stahl announced recent election results at the Annual ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... on November 2nd and New York on November ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... the,Company will present at three upcoming investor conferences: ... Ghalie, M.D., Chief Medical Officer, will present at ...
... (Nasdaq:,SIAL), a life science company dedicated to providing ... and Oxford,BioMedica (LSE: OXB), a leading gene therapy ... confirming the strength and validity of,intellectual property owned ... field to Sigma-Aldrich. The ruling was part of ...
... to "de-cloak" cancers -, TORONTO, Oct. 25 ... company discovering and developing the next wave of,antibody ... from its Trop-2 and CD59 antibody programs. ARIUS ... at the AACR press,conference today at 9:30 a.m. ...
Cached Biology Technology:Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... Scientists at the University of Warwick have discovered that ... , The substance, methylglyoxal - MG, was found ... of bad cholesterol from the body. , Low ... to heart disease, with increased levels of MG being ... kidney problems. , Supported by funding from the ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2
... carried through the atmosphere before settling on the ocean ... new research from the University of Michigan and the ... Earth Science and Technology (SOEST) combines biogeochemistry and direct ... cycle is colliding with ocean fishand the human seafood ...
... members from The University of Texas at Arlington are ... of Texas System Board of Regents for excellence in ... $25,000 cash award and recognize faculty members at UT ... innovation at the undergraduate level. The professors were recognized ...
... Center Researcher Song-Yi Park, PhD, along with her colleagues, ... vegetables may lower the risk of invasive bladder cancer ... part of the Multiethnic Cohort (MEC) Study, established in ... factors, and cancer risk. Park and her fellow researcher,s ...
Cached Biology News:Ocean fish acquire more mercury at depth 2Ocean fish acquire more mercury at depth 3Ocean fish acquire more mercury at depth 49 UT Arlington educators honored for teaching excellence 2
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... Kit is one of the most ... of RNA in solution. The ... than absorbance measurements. As little as ... fluorescence microplate readers and fluorometers using ...
... The GenoStat Inducible Expression System provides tightly ... mammalian cells and is capable of repeated ... is mediated by the highly specific interaction ... bipartite nuclear receptor complex. Gene expression levels ...
Biology Products: